SCHEMBL4251063

SCHEMBL4251063

O=C1COc2c(Cl)ccnc2N1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MALT1 Q9UDY8 2/20 0.38
IL4I1 Q96RQ9 1/20 0.36
MMP12 P39900 1/20 0.36
NR3C2 P08235 4/20 0.35
PGR P06401 3/20 0.35
NR3C1 P04150 2/20 0.35
DAO P14920 1/20 0.35
AR P10275 1/20 0.35
CYP11B1 P15538 1/20 0.35
CYP11B2 P19099 1/20 0.35
MAPT P10636 3/20 0.33
ALDH1A1 P00352 3/20 0.33
PDE3B Q13370 1/20 0.33
PDE3A Q14432 1/20 0.33
CCNB2 O95067 1/20 0.33
CDK1 P06493 1/20 0.33
CCNB1 P14635 1/20 0.33
CDK5 Q00535 1/20 0.33
CDK5R1 Q15078 1/20 0.33
CCNB3 Q8WWL7 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15925944 0.79 MMP12 (0.42) MMP12NR3C2PGRNR3C1AR
SCHEMBL17766364 0.79 PDE3B (0.36) MALT1MMP12NR3C2PGRNR3C1
SCHEMBL10298660 0.77 PARP1 (0.44) MMP12NR3C2CYP11B1CYP11B2MAPT
SCHEMBL9377605 0.76 PDE3B (0.33) MALT1IL4I1MMP12NR3C2PGR
SCHEMBL27051279 0.76 ADRB1 (0.36) MMP12CYP11B1CYP11B2MAPTALDH1A1
SCHEMBL12947787 0.76 MMP12 (0.36) MMP12NR3C2PGRNR3C1CYP11B1
SCHEMBL1190247 0.75 AHR (0.38) MALT1MMP12NR3C2DAOCYP11B1
SCHEMBL4261663 0.74 IL4I1 (0.45) MALT1IL4I1MMP12NR3C2PGR
SCHEMBL31170719 0.74 IL4I1 (0.45) MALT1IL4I1MMP12NR3C2PGR
SCHEMBL31170800 0.74 CES1 (0.41) MALT1IL4I1MMP12NR3C2PGR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9617257-B2 Fused pyridine derivatives useful as c-Met tyrosine kinase inhibitors BETTA PHARMACEUTICALS CO., LTD (CN) 2017-04-11 US disclosed
US-9617257-B2 Fused pyridine derivatives useful as c-Met tyrosine kinase inhibitors BETTA PHARMACEUTICALS CO., LTD (CN) 2017-04-11 US disclosed
US-20150315210-A1 NOVEL FUSED PYRIDINE DERIVATIVES USEFUL AS c-MET TYROSINE KINASE INHIBITORS BETTA PHARMACEUTICALS CO., LTD. (CN) 2015-11-05 US disclosed
US-20150315210-A1 NOVEL FUSED PYRIDINE DERIVATIVES USEFUL AS c-MET TYROSINE KINASE INHIBITORS BETTA PHARMACEUTICALS CO., LTD. (CN) 2015-11-05 US disclosed
US-20090124610-A1 PHARMACEUTICAL COMPOUNDS CANCER RESEARCH TECHNOLOGY LIMITED (GB) 2009-05-14 US disclosed
US-20090124610-A1 PHARMACEUTICAL COMPOUNDS CANCER RESEARCH TECHNOLOGY LIMITED (GB) 2009-05-14 US disclosed
US-20090124610-A1 PHARMACEUTICAL COMPOUNDS CANCER RESEARCH TECHNOLOGY LIMITED (GB) 2009-05-14 US disclosed
WO-2007125320-A1 PHARMACEUTICAL COMPOUNDS ASTEX THERAPEUTICS LIMITED (GB) 2007-11-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150315210-A1 NOVEL FUSED PYRIDINE DERIVATIVES USEFUL AS c-MET TYROSINE KINASE INHIBITORS MET, ABL1, ROS1 MALT1 1557/4885IL4I1 60/4885MMP12 3720/4885
US-20090124610-A1 PHARMACEUTICAL COMPOUNDS GRK3, GRK4, CDK1 MALT1 1224/4885IL4I1 2208/4885MMP12 4538/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.